India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg.
The FDA approved Lupin's Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga for the indications in the approved labelling.
Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
ZYUS Life Sciences receives second US pain management patent
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Photocure study supports cost-effectiveness of blue light cystoscopy
Apotex receives Health Canada approval for a generic Ozempic equivalent
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
Telix Pharmaceuticals' MAA for TLX101-Px (Pixlumi) accepted for European review
FDB introduces gravimetric content to improve IV medication compounding